Clinical Trial Update: Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating transarterial chemoembolization (TACE) in combination with camrelizumab for hepatocellular carcinoma; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING